Development Pipeline
PF-4523655
QPI-1002 for AKI
QPI-1002 for DGF
QPI-1007
siRNA Drug Candidate Pipeline
Letter from the CEO
Company Profile
Management
Board of Directors
Medical Advisory Board
Mission, Vision and Values
Code of Business and Ethics
Partners
News
Careers
Overview
Code of Business and Ethics
News
Overview
R&D Collaborations
Target Discovery
SiRNA
About Us
Product Candidates
Research & Development
Investor Relations
Contact
Development Pipeline
PF-4523655
QPI-1002 for AKI
QPI-1002 for DGF
QPI-1007
siRNA Drug Candidate Pipeline
Letter from the CEO
Company Profile
Management
Board of Directors
Medical Advisory Board
Mission, Vision and Values
Code of Business and Ethics
Partners
News
Careers
Overview
Code of Business and Ethics
News
Overview
R&D Collaborations
Target Discovery
SiRNA
About Us
Product Candidates
Research & Development
Investor Relations
Contact
Development Pipeline
Product:
PF-04523655 (RTP801i14)
Disease:
Diabetic Macular Edema
Technology:
siRNA
Partner:
Pfizer
Product:
PF-04523655 (RTP801i14)
Disease:
Age-related Macular Degeneration
Technology:
siRNA
Partner:
Pfizer
Product:
QPI 1002 (AKIi-5)
Disease:
Acute Kidney Injury (AKI)
Technology:
siRNA
Product:
QPI 1002 (DGFi)
Disease:
Delayed Graft Function
Technology: siRNA
Product:
QPI 1007
Disease:
Ocular Neuroprotection
Technology:
siRNA
Product:
siRNA Pipeline
Disease:
Lung Injury, Cancer,
Neurodegenerative disease,
Others
Technology : siRNA
Development Pipeline
PF-4523655
QPI-1002 for AKI
QPI-1002 for DGF
QPI-1007
siRNA Drug Candidate Pipeline
Home
Products
Contact
©2007 Quark Pharmaceuticals, Inc.